What Insurance Covers Tirzepatide for Weight Loss?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no list of insurers that reliably cover tirzepatide for weight loss, because coverage in this category is decided plan by plan rather than carrier by carrier — and the first thing any plan checks is which tirzepatide product was prescribed and for what. Zepbound holds the chronic weight management indication. Mounjaro contains the same molecule but is indicated only for glycemic control in type 2 diabetes. A weight-based request written against Mounjaro is outside the label, and plans key coverage to the approved indication rather than to the active ingredient.

The First Question Is Whether the Benefit Exists at All

Many employer-sponsored plans exclude anti-obesity medications as a benefit category. That is a different thing from a medical-necessity denial: an excluded category cannot be appealed on clinical grounds, no matter how strong the documentation, because the plan never agreed to cover that class of drug in the first place.

The most useful single question to ask your plan, in writing, is whether anti-obesity medications are an excluded benefit under your specific policy, with a request for the relevant page of the plan document. The answer determines whether the rest of the process is worth your time.

Coverage also varies by market segment. Commercial, exchange, Medicaid and Medicare plans operate under different rules, and a plan that covers a tirzepatide product for one member may not cover it for another under a different policy from the same insurer.

Indication Is the Hinge

Zepbound is approved for chronic weight management in adults with obesity or with overweight plus at least one weight-related condition, in combination with a reduced-calorie diet and increased physical activity. It also holds a separate approval for moderate to severe obstructive sleep apnea in adults with obesity.

That second indication is worth knowing about, because a sleep apnea diagnosis is not a weight reduction claim and some plans treat it differently from their anti-obesity exclusion. If you have a documented diagnosis, it should appear explicitly in the chart rather than by implication.

Mounjaro, by contrast, has no weight-management indication anywhere in its labeling. A plan reviewing a weight-based request for Mounjaro is being asked to fund an off-label use, and off-label prescribing — while lawful — creates no coverage obligation.

What Prior Authorization Typically Asks For

Common requirements include measured height and weight with dates, a calculated body mass index consistent with the labeled population, diagnosis codes for each weight-related condition, and documentation of a prior structured attempt at diet and physical activity. Many plans additionally require a trial of a preferred alternative agent first.

For reference, the pivotal obesity trials enrolled adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbid condition. Payer thresholds often mirror those numbers, but they are set by the payer and not by the FDA.

Continued authorization increasingly requires documented follow-up and demonstrated response. Build that into your expectations from the start, because a renewal denial mid-course has the same practical effect as a discontinuation.

When a Denial Arrives

Every denial states a reason and a deadline. Denials for missing documentation are the easiest to reverse and often need nothing more than a corrected submission. Denials for failure to meet clinical criteria turn on whether the chart supports the criteria as written.

Most plans offer an internal appeal followed by external review by an independent review organisation. A peer-to-peer conversation between your prescriber and the plan’s medical director is frequently the fastest lever on a clinical-criteria denial. Keep every reference number and date, because appeal windows are short and strictly enforced.

If Coverage Is Not Available

Manufacturer savings and direct-purchase programs sit outside the insurance channel and carry their own eligibility rules, which change often enough that they should be verified with the manufacturer directly rather than from any secondary summary.

Compounded tirzepatide is a separate cash-pay category rather than a covered alternative. The FDA states that compounded drugs are not FDA-approved, that the agency does not review them for safety, effectiveness or quality before marketing, and that compounded drugs are not the same as generic drugs, which must establish therapeutic equivalence. There is no approved generic tirzepatide.

Whichever route you use, budget for a long horizon. The evidence on discontinuation is consistent enough that a funding plan lasting only a few months is, in effect, a plan to regain.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Does insurance cover Mounjaro for weight loss?

Generally not, because Mounjaro has no weight-management indication. Its approved use is glycemic control in type 2 diabetes. Plans key coverage decisions to the approved indication rather than to the active ingredient, so a weight-based request written against Mounjaro is an off-label request. Zepbound is the tirzepatide product that carries the chronic weight management indication.

What is the difference between an exclusion and a denial?

An exclusion means the plan does not cover that category of drug at all, so clinical documentation cannot overcome it and it is generally not appealable on medical grounds. A denial means the plan covers the category but concluded your request did not meet its criteria. Denials are appealable, and missing-documentation denials in particular are frequently reversed.

Can a sleep apnea diagnosis change coverage?

It can. Zepbound holds a separate approval for moderate to severe obstructive sleep apnea in adults with obesity, which is a distinct indication from weight reduction. Some plans handle it differently from their anti-obesity exclusion. If you have that diagnosis, have your prescriber document it explicitly rather than leaving it implied by the weight-related history.

What documentation should my prescriber include?

Measured height and weight with dates, a calculated body mass index consistent with the labeled population, diagnosis codes for every weight-related condition, records of prior structured diet and activity interventions and their outcomes, and any relevant laboratory results. Many plans also require evidence of a trial of a preferred alternative and ongoing documented follow-up for renewal.

Is compounded tirzepatide covered by insurance?

Generally not. Compounded preparations are not FDA-approved finished products, the agency does not verify their safety, effectiveness or quality before marketing, and the FDA distinguishes them from generic drugs, which must establish therapeutic equivalence. There is no approved generic tirzepatide, so compounded preparations sit outside the formulary structure that insurance coverage runs through.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.